Utilization of solid CYP1A2 inhibitors should be discontinued before initiating pirfenidone and averted for the duration of therapy; if potent CYP1A2 inhibitors are the one drug of preference, dosage reductions are encouraged Disclosures: Muotri is really a co-founder and has an equity curiosity in TISMOO, an organization focused on genetic https://edgarz211lwh4.wikiworldstock.com/user